Complementary analysis of relationships between daily salt intake and the outcomes. Table S1. Prevalence of hypertension based on the 2017 ACC/AHA and JNC8 hypertension guidelines and individual characteristics associated with prevalence according to the 2017 ACC/AHA guideline. Table S2. Percentage of hypertension awareness based on the 2017 ACC/AHA and JNC8 hypertension guidelines and individual characteristics associated with awareness according to the 2017 ACC/AHA guideline. Table S3. Percentage of hypertension treatment based on the 2017 ACC/AHA and JNC8 hypertension guidelines and individual characteristics associated with treatment according to the 2017 ACC/AHA guideline. Table S4. Percentage of hypertension control based on the 2017 ACC/AHA and JNC8 hypertension guidelines and individual characteristics associated with hypertension control according to the 2017 ACC/AHA guideline.
Jnc 8 Guidelines Free Pdf 11
The rationale in guidelines that recommended lower treatment targets (below 7 percent or below 6.5 percent) is that more intensive blood sugar control would reduce microvascular complications over many years of treatment. However, the evidence for reduction is inconsistent and reductions were seen only in surrogate microvascular complications such as the presence of excess proteins in the urine.
Background: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This document describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspecialty physicians and others providing care for patients with this condition.
Methods: The American Thyroid Association (ATA) previously cosponsored guidelines for the management of thyrotoxicosis that were published in 2011. Considerable new literature has been published since then, and the ATA felt updated evidence-based guidelines were needed. The association assembled a task force of expert clinicians who authored this report. They examined relevant literature using a systematic PubMed search supplemented with additional published materials. An evidence-based medicine approach that incorporated the knowledge and experience of the panel was used to update the 2011 text and recommendations. The strength of the recommendations and the quality of evidence supporting them were rated according to the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation Group.
Results: Clinical topics addressed include the initial evaluation and management of thyrotoxicosis; management of Graves' hyperthyroidism using radioactive iodine, antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma using radioactive iodine or surgery; Graves' disease in children, adolescents, or pregnant patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves' orbitopathy; and management of other miscellaneous causes of thyrotoxicosis. New paradigms since publication of the 2011 guidelines are presented for the evaluation of the etiology of thyrotoxicosis, the management of Graves' hyperthyroidism with antithyroid drugs, the management of pregnant hyperthyroid patients, and the preparation of patients for thyroid surgery. The sections on less common causes of thyrotoxicosis have been expanded. 2ff7e9595c
Comments